Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immutep Ltd ADR
(NQ:
IMMP
)
1.820
+0.005 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immutep Ltd ADR
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
April 24, 2024
From
Immutep Limited
Via
GlobeNewswire
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
October 24, 2023
From
Immutep Limited
Via
GlobeNewswire
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
October 23, 2023
From
Immutep Limited
Via
GlobeNewswire
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 17, 2023
From
Immutep Limited
Via
GlobeNewswire
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
May 01, 2023
From
Immutep Limited
Via
GlobeNewswire
Why Did Immutep Ltd Stock Soar Recently?
December 28, 2022
Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
November 29, 2022
From
Immutep Limited
Via
GlobeNewswire
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
November 09, 2022
From
Immutep Limited
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.